Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has been given an average rating of “Buy” by the eight research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $41.25.

A number of analysts recently issued reports on ACRS shares. ValuEngine upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Cantor Fitzgerald started coverage on Aclaris Therapeutics in a research report on Friday, June 16th. They issued an “overweight” rating and a $50.00 price target for the company. Jefferies Group LLC restated a “buy” rating and issued a $36.00 price target on shares of Aclaris Therapeutics in a research report on Wednesday, June 28th. Guggenheim restated a “buy” rating and issued a $40.00 price target on shares of Aclaris Therapeutics in a research report on Tuesday, July 4th. Finally, BidaskClub upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, July 24th.

In other Aclaris Therapeutics news, Director Andrew N. Schiff bought 108,601 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The stock was acquired at an average cost of $23.02 per share, for a total transaction of $2,499,995.02. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 16.30% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in ACRS. Citigroup Inc. raised its holdings in shares of Aclaris Therapeutics by 171.8% in the second quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 2,726 shares in the last quarter. UBS Group AG raised its holdings in shares of Aclaris Therapeutics by 60.4% in the first quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 1,681 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Aclaris Therapeutics by 98.3% in the second quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock valued at $142,000 after acquiring an additional 2,605 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of Aclaris Therapeutics by 1,793.1% in the second quarter. Bank of Montreal Can now owns 7,137 shares of the biotechnology company’s stock valued at $194,000 after acquiring an additional 6,760 shares in the last quarter. Finally, Nationwide Fund Advisors raised its holdings in shares of Aclaris Therapeutics by 8.3% in the first quarter. Nationwide Fund Advisors now owns 6,627 shares of the biotechnology company’s stock valued at $198,000 after acquiring an additional 510 shares in the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Aclaris Therapeutics, Inc. (ACRS) Receives Consensus Rating of “Buy” from Analysts” was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/11/aclaris-therapeutics-inc-acrs-receives-consensus-rating-of-buy-from-analysts.html.

Shares of Aclaris Therapeutics (ACRS) traded down 1.70% during midday trading on Wednesday, hitting $26.57. 661,855 shares of the stock were exchanged. Aclaris Therapeutics has a 52-week low of $20.15 and a 52-week high of $33.25. The firm’s 50-day moving average is $26.07 and its 200 day moving average is $27.12. The firm’s market cap is $710.40 million.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.12. On average, analysts forecast that Aclaris Therapeutics will post ($3.10) earnings per share for the current year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.